Nuo Therapeutics ROE 2024

Nuo Therapeutics ROE

-3.05

Nuo Therapeutics Dividend yield

Ticker

AURX

ISIN

US67059V2097

WKN

A2AP5P

In 2024, Nuo Therapeutics's return on equity (ROE) was -3.05, a 110.84% increase from the -1.45 ROE in the previous year.

Nuo Therapeutics Aktienanalyse

What does Nuo Therapeutics do?

Nuo Therapeutics Inc is a US-American company specializing in the development and marketing of medical products and therapies for wound healing. The company was originally founded in 2002 as Cytomedix and was renamed Nuo Therapeutics in 2016. The company's history stems from the discovery of growth factors produced by human platelets, which play an important role in wound healing. Research has shown that these growth factors can be used to expedite wound healing, making it a promising approach for the development of new medical therapies. Nuo Therapeutics aims to develop and bring innovative wound healing products and therapies to the market. The company specializes in three main areas: biosurgery, dermatology, and advanced wound care. In the biosurgery division, Nuo Therapeutics offers a range of medical products that can be used for hemostasis and wound care. This includes Nexagon® Gel, a wound treatment product based on the aforementioned growth factors, and SurgiWrapTM, a barrier membrane for the protection of surgically treated soft tissues. In the dermatology division, Nuo Therapeutics focuses on the development of therapeutic products for the treatment of skin conditions such as eczema, psoriasis, and acne. To this end, the company has entered into an agreement with a leading pharmaceutical company to develop the skincare product SECUAADTM. The advanced wound care division of Nuo Therapeutics focuses on the treatment of difficult, chronic wounds that do not heal. In this area, the company has acquired the rights to a unique technology called AurixTM, which is based on the use of growth factors from the patient's own blood. With AurixTM, Nuo Therapeutics aims to help patients with hard-to-heal wounds heal their wounds faster and more safely. The business model of Nuo Therapeutics is based on the development and commercialization of innovative medical products and therapies. The company relies on partnerships with other companies in the pharmaceutical and medical industries to support the development and marketing of its products. Nuo Therapeutics has experienced strong growth in recent years and has established itself as a key player in the market for medical wound healing products. With its innovative products and therapies, the company is well positioned to continue growing in the future and make a significant contribution to improving medical care for patients worldwide. Nuo Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Nuo Therapeutics's Return on Equity (ROE)

Nuo Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Nuo Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Nuo Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Nuo Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Nuo Therapeutics Stock

What is the ROE (Return on Equity) of Nuo Therapeutics this year?

The ROE of Nuo Therapeutics this year is -3.05 undefined.

How has the Return on Equity (ROE) of Nuo Therapeutics developed compared to the previous year?

The ROE of Nuo Therapeutics has increased by 110.84% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Nuo Therapeutics?

A high ROE indicates that Nuo Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Nuo Therapeutics?

A low ROE can indicate that Nuo Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Nuo Therapeutics affect the company?

A change in ROE (Return on Equity) of Nuo Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Nuo Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Nuo Therapeutics?

Some factors that can influence Nuo Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Nuo Therapeutics pay?

Over the past 12 months, Nuo Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nuo Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nuo Therapeutics?

The current dividend yield of Nuo Therapeutics is .

When does Nuo Therapeutics pay dividends?

Nuo Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nuo Therapeutics?

Nuo Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nuo Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nuo Therapeutics located?

Nuo Therapeutics is assigned to the '-' sector.

Wann musste ich die Aktien von Nuo Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nuo Therapeutics from 5/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.

When did Nuo Therapeutics pay the last dividend?

The last dividend was paid out on 5/30/2024.

What was the dividend of Nuo Therapeutics in the year 2023?

In the year 2023, Nuo Therapeutics distributed 0 USD as dividends.

In which currency does Nuo Therapeutics pay out the dividend?

The dividends of Nuo Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nuo Therapeutics

Our stock analysis for Nuo Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuo Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.